↑ 薬物リストへ　← 戻る

Polyphenon e    (DrugBank: -)

2 diseases
告示番号疾患名（ページ内リンク）臨床試験数
13多発性硬化症／視神経脊髄炎2
36表皮水疱症2

13. 多発性硬化症／視神経脊髄炎　［臨床試験数：3,050，薬物数：2,147（DrugBank：348），標的遺伝子数：244，標的パスウェイ数：228］
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 3,050 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01451723
(ClinicalTrials.gov)		July 201111/10/2011Safety and Neuroprotective Effects of Polyphenon E in MS; Phase IIPhase 2 Randomized Placebo Controlled Trial of Polyphenon E in MSMultiple SclerosisDrug: Polyphenon E;Other: PlaceboLouisiana State University Health Sciences Center in New OrleansNational Center for Complementary and Integrative Health (NCCIH)Terminated18 Years60 YearsAll11Phase 2United States
2NCT00836719
(ClinicalTrials.gov)		February 20093/2/2009Safety of Polyphenon E in Multiple Sclerosis Pilot StudySafety and Neuroprotective Effects of Polyphenon E in Multiple SclerosisMultiple SclerosisDrug: Polyphenon ELouisiana State University Health Sciences Center in New OrleansNational Center for Complementary and Integrative Health (NCCIH)Completed18 Years65 YearsAll10Phase 1United States

36. 表皮水疱症　［臨床試験数：147，薬物数：170（DrugBank：40），標的遺伝子数：32，標的パスウェイ数：113］
Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 147 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00951964
(ClinicalTrials.gov)		October 20103/8/2009Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)Epidermolysis Bullosa DystrophicaDrug: Polyphenon E before Placebo;Drug: placebo before treatmentCentre Hospitalier Universitaire de NiceNULLCompleted2 YearsN/ABoth18Phase 2France
2EUCTR2009-012750-21-FR
(EUCTR)		20/01/201027/11/2009Traitement des épidermolyses bulleuses dystrophiques héréditaires parl’épigallocatéchine-3-gallate oral (Polyphenon E®)Traitement des épidermolyses bulleuses dystrophiques héréditaires parl’épigallocatéchine-3-gallate oral (Polyphenon E®) Dystrophic epidermolysis bullosa hereditaria
MedDRA version: 12.0;Level: LLT;Classification code 10056508;Term: Acquired epidermolysis bullosa		Trade Name: POLYPHENON E
Product Name: POLYPHENON E		CHU de NICENULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		France